The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | CAPTIVATE study: outcomes in patients with uMRD following cessation of ibrutinib plus venetoclax
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Australia, reports follow-up results from the CAPTIVATE trial (NCT02910583), comparing the outcomes of patients with chronic lymphocytic leukemia (CLL) who received continued ibrutinib (Ibr) therapy or who stopped ibrutinib treatment after achieving undetectable measurable residual disease (uMRD) after Ibr plus venetoclax (Ven) induction therapy. The study reported no clinical benefit of continuing Ibr treatment after achieving uMRD. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; LOXO: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria, Research Funding.
